Short answer
Alkermes plc. (ALKS) filed an 8-K current report with the SEC on May 12, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Alkermes disclosed positive topline results under Regulation FD, making the update broadly available to investors.
Alkermes plc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Alkermes disclosed positive topline results under Regulation FD, making the update broadly available to investors
- Clinical or program details are contained in the referenced May 12, 2026 press release
- Market relevance depends on the results’ implications for development, regulatory progress, and potential commercialization
Item 8.01 · Other Events
- Positive topline Phase 3 REVITALYZ results support LUMRYZ’s potential expansion into idiopathic hypersomnia
- Randomized, placebo-controlled design provides clinical evidence for regulatory and commercial decisions
- New indication could broaden LUMRYZ’s addressable market beyond its current use cases
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Alkermes plc. 8-K filings
Get the next ALKS 8-K as it lands
Follow ALKS for push alerts, or ask the research agent what this filing means.